Zealand Pharma A/S
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Adam Sinding Steensberg
- Full Time Employees
- 481
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Sydmarken 11 Soborg Denmark 2860
- IPO Date
- Dec 23, 2010
- Website
- zealandpharma.com
- Similar Companies
- Business
- Zealand Pharma A/S is a biotechnology company focused on the discovery, design, development and commercialization of innovative peptide-based medicines targeting obesity, rare diseases including congenital hyperinsulinism and short bowel syndrome, and chronic inflammation; its marketed products include Zegalogue (dasiglucagon injection) for treatment of severe hypoglycemia in people aged four and above and V-Go for insulin delivery in diabetes management; its R&D pipeline features petrelintide, a long-acting amylin analog for weight management; dapiglutide, a long-acting GLP-1/GLP-2 dual agonist targeting obesity and inflammation; survodutide, a glucagon/GLP-1 dual agonist licensed to Boehringer Ingelheim for obesity and MASH; ZP6590, a GIP receptor agonist for obesity; dasiglucagon for continuous subcutaneous infusion in congenital hyperinsulinism; glepaglutide, a long-acting GLP-2 analog for short bowel syndrome; ZP9830, a Kv1.3 ion channel blocker for T-cell driven autoimmune diseases; and ZP10068, a complement C3 inhibitor for complement-mediated diseases. Zealand Pharma A/S, founded in 1998, is headquartered in Søborg, Denmark, and maintains operations including a U.S. team targeting global markets through partnerships. Recent developments include a March 2025 collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide as a foundational obesity therapy including fixed-dose combinations with Roche's CT-388, providing upfront payments of USD 1.65 billion and potential total value up to USD 5.3 billion with 50/50 profit sharing in the U.S. and Europe; closure of the Roche deal in May 2025; initiation of the ZUPREME-2 Phase 2 trial for petrelintide in obesity patients with type 2 diabetes; a 2024 equity offering raising approximately USD 900 million to fund obesity programs and R&D; and progression of Phase 2 and 3 readouts for petrelintide and survodutide.
Company News
Zealand Pharma A/S (OTCMKTS:ZLDPF) Sets New 52-Week Low – Time to Sell?
Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Should You Sell?
Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Rating of “Hold” from Brokerages
Zealand Pharma's short bowel syndrome drug wins backing from EU panel
Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
Drugmakers race to find a place in the next wave of obesity drugs
Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot's Side Effects
Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
Zealand Pharma shares drop 20% as obesity drug side effects raise concerns
Is Zealand Pharma AS (ZLDPF) Stock Undervalued Right Now?
Zealand Pharma A/S (ZLDPY) Q1 2026 Earnings Call Transcript
Zealand Pharma A/S (ZLDPF) Reports Q1 Loss, Lags Revenue Estimates
Zealand Pharma posts smaller-than-expected Q1 loss as obesity drugs advance
Comparing Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Zealand Pharma A/S (OTCMKTS:ZLDPF)
Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Zealand Pharma A/S (ZLDPF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Disappointing weight-loss-trial results from Zealand Pharma sends shares tumbling
Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
Zealand Pharma A/S (ZLDPF) Discusses Top Line Phase II Results for ZUPREME-1 Trial of Petrelintide in Obesity Transcript